Grifols (GRFS) Non-Current Assets (2009 - 2025)
Grifols' (GRFS) quarterly Non-Current Assets came in at $17.0 billion in Q4 2025, up 1.71% YoY from $16.8 billion in Q4 2024, and up 1.71% on a QoQ basis from $16.8 billion in Q4 2024.
Grifols (GRFS) Non-Current Assets (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Non-Current Assets data on file, last reported at $17.0 billion in Q4 2025.
- Quarterly Non-Current Assets rose 1.71% year-over-year to $17.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $66.7 billion (up 4.74% YoY) and the FY2025 annual result came in at $17.0 billion, up 31454.2% from the prior year.
- Non-Current Assets climbed to $17.0 billion in Q4 2025, from $16.8 billion in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $17.0 billion in Q4 2025 to a low of $15.7 billion in Q4 2021.
- A 5-year average of $16.5 billion and a median of $16.8 billion in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2021 — Non-Current Assets climbed 8.73% — and 2023, when it declined 5.24%.
- Tracing GRFS's Non-Current Assets over 5 years: stood at $15.7 billion in 2021, then increased by 7.48% to $16.9 billion in 2022, then dropped by 5.24% to $16.0 billion in 2023, then gained by 4.77% to $16.8 billion in 2024, then advanced by 1.71% to $17.0 billion in 2025.
- The last three Non-Current Assets figures came in at $17.0 billion (Q4 2025), $16.8 billion (Q4 2024), and $16.0 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.59 Bn | 463.02 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 375.61 Bn | 368.47 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 302.64 Bn | 294.95 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.53 Bn | 252.63 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 236.78 Bn | 222.79 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 183.22 Bn | 180.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.95 Bn | 101.79 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Grifols | 5.46 Bn | 4.46 Bn | - | 17.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 17.04 Bn |
| Dec 31, 2024 | 16.75 Bn |
| Dec 31, 2023 | 15.99 Bn |
| Dec 31, 2022 | 16.87 Bn |
| Dec 31, 2021 | 15.70 Bn |
| Dec 31, 2020 | 14.44 Bn |
| Sep 30, 2020 | 14.02 Bn |
| Mar 31, 2020 | 13.50 Bn |
| Dec 31, 2019 | 11.27 Bn |
| Sep 30, 2019 | 11.55 Bn |
| Mar 31, 2019 | 11.25 Bn |
| Dec 31, 2018 | 10.27 Bn |
| Sep 30, 2018 | 10.18 Bn |
| Jun 30, 2018 | 10.13 Bn |
| Mar 31, 2018 | 12.80 Bn |
| Dec 31, 2017 | 9.39 Bn |
| Jun 30, 2017 | 9.09 Bn |
| Dec 31, 2016 | 7.57 Bn |
| Sep 30, 2016 | 7.38 Bn |
| Jun 30, 2016 | 7.48 Bn |